Clinical Trial Update: LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial assessing nintedanib added to paclitaxel and carboplatin vs placebo in first-line treatment of ovarian cancer; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Nintedanib (BIBF 1120) (nintedanib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Ovarian Neoplasms, Peritoneal Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2015-01-15